Blood-brain barrier tight junction permeability and ischemic stroke.
By Karin E. Sandoval, K. Witt. Neurobiology of Disease, 2008
930 citations recorded by the source corpus.
The blood-brain barrier (BBB) is formed by the endothelial cells of cerebral microvessels, providing a dynamic interface between the peripheral circulation and the central nervous system. The tight junctions (TJs) between the endothelial cells serve to restrict blood-borne substances from entering the brain. Under ischemic stroke conditions decreased BBB TJ integrity results in increased paracellular permeability, directly contributing to cerebral vasogenic edema, hemorrhagic transformation, and increased mortality. This loss of TJ integrity occurs in a phasic manner, which is contingent on several interdependent mechanisms (ionic dysregulation, inflammation, oxidative and nitrosative stress, enzymatic activity, and angiogenesis). Understanding the inter-relation of these mechanisms is critical for the development of new therapies. This review focuses on those aspects of ischemic stroke impacting BBB TJ integrity and the principle regulatory pathways, respective to the phases of paracellular permeability.
Subfields: Epidemiology, Neurology
View Paper: https://www.semanticscholar.org/paper/379e1b39377c5f70c643aa17a65bb8e056cd2da0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Neurology
- M. Sofroniew
- Sanjay M. Sisodiya
- Heidrun Potschka
- Wolfgang Löscher
- Xiaowei Dong
- N. Ferrara
- A. Vezzani
- J. Burda
Citations in the corpus
- Current Strategies for Brain Drug Delivery (2018, background): “Delivery through the permeable BBB under disease conditions Potential to cross the BBB Limited knowledge about dynamic changes in the BBB and their mechanisms [63], [70-72], [75-76],”
- Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. (2012, background): “matory CNS conditions, including MS (13), viral encephalitis (14), and traumatic and hypoxic/ischemic injury (15).”
- Crossing the blood‐brain barrier with nanoparticles (2018, background): “Due to the presence of tight junctions instead of large fenestration between endothelial cells, the passage of the drugs through the BBB is primarily restricted [22].”
- The blood-brain barrier in systemic inflammation. (2017, neutral): “Stroke The BBB is disrupted in ischaemic stroke (Sandoval and Witt, 2008), and is sensitised to further disruptive changes by systemic inflammation (Denes et al., 2011).”
- Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. (2018, methodology): “BBB was evoked at 5 and 72 h of reperfusion respect ively [61,62].”
- Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options (2020, background): “The activation of the VEGFVEGFR2 axis in astrocytes and vessels alters extracellular matrix and tight junctions, respectively, thereby contributing to BBB dysfunction (reviewed in Sandoval and Witt, 2008).”
- Stepwise Recruitment of Transcellular and Paracellular Pathways Underlies Blood-Brain Barrier Breakdown in Stroke (2014, neutral): “P A A uthor M anuscript (Sandoval and Witt, 2008); however our data do not support this model.”